Lobaplatin is named as a drug or biological intervention in 4 clinical trials in our China trial register, 2 of which are recruiting. Lead sponsors include Sun Yat-sen University (1), Xijing Hospital (1) and Peking University People's Hospital (1). Registered phases: Phase 2, Phase 3 and Phase 4. Conditions studied include Nasopharyngeal Carcinoma; Leucogen; Chemotherapy.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06586242 | Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy (ClinicalTrials.gov ↗) Esophageal Cancer |
Phase 2 | Recruiting |
| NCT06714383 | Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma (ClinicalTrials.gov ↗) Osteosarcoma |
Phase 2 | Recruiting |
| NCT07093931 | Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer |
Phase 4 | Not yet open |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Leucogen, Chemotherapy |
Phase 3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Nasopharyngeal Carcinoma | 1 |
| Leucogen | 1 |
| Chemotherapy | 1 |
| Myelosuppression | 1 |
| Esophageal Cancer | 1 |
| Osteosarcoma | 1 |
| Breast Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Sun Yat-sen University | 1 |
| Xijing Hospital | 1 |
| Peking University People's Hospital | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| Register | Lobaplatin trials |
|---|---|
| Clinical trials in China | 4 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Lobaplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Lobaplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.